HOTH - Hoth Therapeutics partner discloses positive preclinical results for COVID-19 vaccine

HaloVax, a vaccine candidate targeting COVID-19 has demonstrated positive data from its second set of preclinical animal testing, Voltron Therapeutics said.Developed in partnership with Hoth Therapeutics (HOTH), HaloVax is built on a base of a heat shock protein (HSP70)-Avidin fusion protein, unlike many other vaccine efforts that use adjuvants such as alum.The study consisting of what the company called ‘a full near’ GLP (good laboratory practice) preclinical mouse study has evaluated whether HaloVax leads to an increase in the immune response relative to controls or peptides alone.Based on results, Voltran said that compared to the controls, HaloVax has significantly increased both helper and cytotoxic T cell responses to the targeted antigens.According to the company, the proof of concept of the platform is critical to both the COVID-19 program as well as an oncology application based on this technology.Yesterday, Hoth Therapeutics surged in reaction to new in-vitro data of its experimental COVID-19 therapeutic

For further details see:

Hoth Therapeutics partner discloses positive preclinical results for COVID-19 vaccine